Streetbeat News

RHHBY

Roche Holding AG

CEO

Severin Schwan

Industry

Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

Open

42.57

Mkt cap

278B

Volume

213K

High

43.31

P/E Ratio

29.63

52-wk high

43.96

Low

42.56

Div yield

N/A

52-wk low

29.20

Roche missed out on acquiring a potential blockbuster weight-loss drug, orforglipron, which Eli Lilly acquired for $50 million and is projected to generate up to $14 billion annually by 2032. Roche's cautious approach, influenced by past setbacks, led to this missed opportunity. Roche re-entered the obesity market in 2023 but is expected to lag behind competitors like Eli Lilly and Novo Nordisk.

Portfolio Pulse from Vandana Singh

August 16, 2024 | 5:56 pm

Tempest Therapeutics Inc. (NASDAQ:TPST) announced positive feedback from its end-of-Phase 2 meeting with the FDA for its drug amezalpat (TPST-1120) in combination with atezolizumab and bevacizumab to treat hepatocellular carcinoma (HCC). The FDA and Tempest are in broad agreement on the design and statistical plan for the pivotal Phase 3 clinical trial, which is set to start in Q1 2025. TPST stock surged 34.90% following the announcement.

Portfolio Pulse from Vandana Singh

August 15, 2024 | 5:15 pm

Syros Pharmaceuticals (NASDAQ:SYRS) announced the discontinuation of its SELECT-AML-1 Phase 2 trial for a leukemia treatment due to disappointing interim results. The trial compared a triplet regimen including tamibarotene, venetoclax (marketed by AbbVie Inc. and Roche Holdings AG), and azacitidine (marketed by Bristol Myers Squibb & Co) to a doublet regimen. The stock of Syros Pharmaceuticals dropped by 60.50% following the news.

Portfolio Pulse from Vandana Singh

August 13, 2024 | 1:41 pm

Merck & Co Inc (NYSE:MRK) has discontinued its Phase 3 KeyVibe-008 trial for a Keytruda combination due to ineffective results and higher adverse events. The trial compared the combination to Roche's Tecentriq for treating extensive-stage small cell lung cancer. Merck is notifying investigators and offering alternative treatments. The stock is up 0.82% following the announcement.

Portfolio Pulse from Vandana Singh

August 08, 2024 | 3:51 pm

Roche Holding AG is considering selling Flatiron Health, a cancer data specialist it acquired in 2018 for $1.9 billion. The move highlights the challenges large pharmaceutical companies face when investing in early-stage health tech firms. Flatiron's association with Roche has deterred some rival drugmakers, impacting its sales. Roche is working with Citigroup to explore strategic options for Flatiron, including a potential divestiture or partial sale.

Portfolio Pulse from Vandana Singh

August 07, 2024 | 3:25 pm

Bristol Myers Squibb (BMY) has terminated its license, development, and commercialization agreement with Agenus Inc (AGEN) for the cancer drug AGEN1777. This decision is part of a broader strategic realignment. The termination will be effective from January 26, 2025. The news follows recent failures of similar TIGIT drugs from Roche (RHHBY) and Merck (MRK). AGEN's stock dropped 7.10% following the announcement.

Portfolio Pulse from Vandana Singh

August 05, 2024 | 6:31 pm

Roche Holding reported its H1 adjusted EPS of CHF 10.23, up from CHF 10.10 year-over-year, and revenue of CHF 29.85 billion, up from CHF 29.78 billion year-over-year.

Portfolio Pulse from Benzinga Newsdesk

July 25, 2024 | 7:38 am

Novo Nordisk's stock dipped 1.25% in pre-market trading despite the UK approving its weight loss drug, Wegovy, for reducing heart complications in overweight adults. Increased competition from Pfizer and Roche in the weight loss drug market also contributed to the decline.

Portfolio Pulse from Benzinga Neuro

July 24, 2024 | 10:57 am

The development of oral weight loss medications is gaining momentum with companies like Eli Lilly, Novo Nordisk, Pfizer, and Roche leading the charge. While oral drugs offer advantages over injectables, such as reduced costs and no need for refrigeration, they face challenges like production issues and potential side effects. Novo Nordisk's Rybelsus is currently the only authorized oral GLP-1 drug, but other companies are making significant progress in clinical trials.

Portfolio Pulse from Vandana Singh

July 22, 2024 | 5:42 pm

Eli Lilly and Novo Nordisk faced significant stock declines as new competitors entered the weight-loss drug market. Pfizer and Roche announced advancements in obesity treatments, challenging the duopoly of Eli Lilly's Zepbound and Novo Nordisk's Wegovy. The Tema GLP-1, Obesity and Cardiometabolic ETF (HRTS) fund reflects a diversified approach, investing in emerging GLP-1 players like Amgen, Terns Pharmaceuticals, and Viking Therapeutics.

Portfolio Pulse from Piero Cingari

July 18, 2024 | 8:59 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.